Is nintedanib a life-saving drug for lung disease patients?

Nintedanib (Nintedanib), as a multi-target tyrosine kinase inhibitor, is widely used in the global medical community, especially in the field of respiratory medicine, to treat idiopathic pulmonary fibrosis (IPF) and other progressive interstitial lung diseases (ILDs). Its mechanism is mainly by inhibiting various tyrosine kinase signaling pathways including FGFR, VEGFR and PDGFR, thereby blocking key cell proliferation and migration in the fibrosis process, and delaying the abnormal proliferation and fibrosis process of lung interstitial tissue.

Although the term "life-saving drug" needs to be used with caution in medicine, nintedanib can indeed be regarded to some extent as an important life-extending tool for patients with pulmonary fibrosis. Pulmonary fibrosis is an irreversible, chronic and progressive disease. Without effective intervention, the patient's lung function will continue to deteriorate and may eventually develop into respiratory failure. The clinical value of nintedanib does not lie in completely curing the disease, but in significantly delaying the progression of the disease, maintaining stable lung function, and reducing the risk of acute exacerbations. It brings "controllable" hope to many patients diagnosed with mid-to-late stage IPF or other related fibrotic lung diseases, and is one of the core options for drug treatment at this stage.

Many foreign studies and guidelines list nintedanib as a first-line drug for the treatment of IPF. In addition, the drug has also been expanded to treat interstitial lung diseases caused by other causes, such as systemic sclerosis-associated interstitial lung disease (SSc-ILD), further solidifying its status as a "gatekeeper" for pulmonary fibrosis.

It is worth mentioning that the use of nintedanib needs to be weighed against side effects, such as diarrhea and elevated liver enzymes. Therefore, it is more suitable as a long-term maintenance treatment after a comprehensive evaluation by a doctor, rather than as an "emergency life-saving" drug. But it is undeniable that it plays an important role in delaying the decline of lung function and reducing the risk of mortality. For many lung disease patients, nintedanib has indeed improved the quality of life and hope, and is regarded as a "turning point in life."

Reference materials:https://en.wikipedia.org/wiki/Nintedanib